Drug Profile
Ecopipam - Emalex Biosciences
Alternative Names: EBS-101; Ecopipam HCl; PSYRX 101; SCH-39166Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Emalex Biosciences; Psyadon Pharmaceuticals; Schering-Plough
- Class Alcohols; Antipsychotics; Behavioural disorder therapies; Benzazepines; Cardiovascular therapies; Chlorinated hydrocarbons; Drug withdrawal therapies; Heterocyclic compounds with 4 or more rings; Naphthalenes; Obesity therapies; Small molecules
- Mechanism of Action Dopamine D1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome
- Phase II Speech disorders
- Phase I/II Restless legs syndrome
- Phase I Cardiovascular disorders
- No development reported Gambling
- Discontinued Cocaine-related disorders; Obesity; Schizophrenia
Most Recent Events
- 18 Jan 2024 Emalex Biosciences initiates a phase I drug-drug interaction trial (In Volunteers) in Canada (NCT06194864)
- 08 Jan 2024 Emalex Biosciences plans a phase I drug drug interaction trial (In Volunteers) in Canada, in January 2024 (NCT06194864)
- 05 Oct 2023 Efficacy and adverse events data from a phase II trial in Gilles de la Tourette's syndrome released by Emalex Biosciences